Novo Nordisk stock gains on CHMP Frehemgo boost and USD 1.4 billion Orbis deal

Novo Nordisk stock (ISIN DK0060534915) is in focus on September 18, 2026 after regulators in Europe backed its new hemophilia A drug Frehemgo and the company signed a drug discovery deal with Orbis Medicine worth up to USD 1.4 billion, while recent trial data support a convenient pen injector for hemophilia patients.

CHMP backs Frehemgo for hemophilia A

According to Novo Nordisk on September 17, 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorisation for FREHEMGO (denecimig) to treat hemophilia A in adults and children, with or without inhibitors.

The company stated that Frehemgo is the first factor VIIIa mimetic offering prophylactic dosing as infrequently as once monthly, with alternative once every two weeks and weekly schedules delivered via a pre-filled pen, which is designed to make long-term prevention of bleeding episodes more convenient for patients.

As Novo Nordisk highlights, denecimig showed tolerability when patients switched from emicizumab in the Phase 3b FRONTIER5 study, and this safety profile underpins the regulatory push in Europe for broad use across different hemophilia A patient groups.

AI partnerships and Orbis deal expand pipeline

On the strategic side, Novo Nordisk is pairing its biologics expertise with artificial intelligence to broaden its cardiometabolic and rare disease pipeline.

According to GuruFocus on September 17, 2026, Novo Nordisk announced a partnership with Orbis Medicine valued at up to USD 1.4 billion to develop innovative oral macrocycle therapies for cardiometabolic diseases using AI-driven drug discovery, with the structure including upfront investment, milestone payments and tiered royalties.

As Aktiencheck reports, Novo Nordisk is preparing for a capital markets day in London on September 21, 2026, where it plans to present its updated corporate strategy, and investors will be watching how AI partnerships and new modalities like oral macrocycles are positioned alongside its established GLP-1 franchise.

In addition, Semafor reported on September 17, 2026 that Novo Nordisk has partnered with AI company Anthropic to use its Claude models to accelerate discovery and development of new medicines, indicating that the drugmaker sees AI as a lever to regain market share in obesity and adjacent areas after its shares fell about 20% over the past year.

Hemophilia data support denecimig pen injector

Beyond the CHMP stance, trial data suggest that denecimig could offer a practical upgrade in hemophilia care.

According to GuruFocus, Novo Nordisk recently disclosed results from the Phase 3b FRONTIER5 trial, where patients transitioning from emicizumab vial and syringe to a subcutaneous denecimig pen injector over 26 weeks showed no unexpected safety issues and preferred the pen device for ease of use.

The same report notes that thrombin peak levels improved without signs of excessive clotting in FRONTIER5, which the company and observers see as an encouraging pharmacodynamic signal that denecimig may reduce bleeding risk while maintaining a manageable safety profile compared with existing prophylactic regimens.

As GuruFocus points out, these hemophilia advances come as Novo Nordisk is viewed as materially undervalued on a discounted cash flow basis and maintains a robust dividend, which could be supportive for long-term shareholders if pipeline execution continues.

Capital allocation and shareholder returns

Alongside pipeline investments, Novo Nordisk is returning substantial cash to shareholders through buybacks.

According to Trading-Treff, by September 11, 2026 the company had repurchased 33,084,179 B-shares at an average price of 281.89 Danish kroner, for a total consideration of about 9.33 billion Danish kroner under its ongoing buyback program.

This buyback volume, at an average price equivalent to more than the current euro-denominated trading level cited in the same article, underlines management's conviction in the long-term earnings power of Novo Nordisk despite recent share price volatility.

As GuruFocus calculates, based on a GF Value estimate of USD 104.84 per American Depositary Receipt and a market price of USD 41.71, Novo Nordisk appears about 60.2% undervalued on that methodology, although investors should treat any single valuation model with caution.

Risks: ziltivekimab setback and competition

Not all recent developments have been positive, and they highlight the execution risks in Novo Nordisk's diversification strategy.

As Yahoo Finance summarized from Reuters on September 7, 2026, Novo Nordisk halted two additional trials of its experimental cardiovascular drug ziltivekimab after an earlier late-stage study failed to reduce major adverse cardiovascular events, with an independent data monitoring committee seeing a low likelihood that the remaining heart failure studies would yield different results.

This decision reduces the near-term prospects of ziltivekimab as a diversification pillar beyond the blockbuster obesity and diabetes franchise and may increase investor focus on how quickly pipeline assets like denecimig and AI-enabled cardiometabolic programs can fill the gap.

According to Semafor, Novo Nordisk shares have fallen about 20% over the past year, a move that reflects both intensified competition in GLP-1 therapies and investor concerns about the sustainability of extremely high growth rates in obesity drugs.

Next strategy update and investor focus

Looking ahead, investors will soon get more detail on how Novo Nordisk plans to balance cash returns, obesity expansion and pipeline investment.

As Trading-Treff notes, the company has scheduled a capital markets day in London for September 21, 2026 to present its revised corporate strategy, with topics expected to include the Frehemgo launch timeline, AI collaborations and ongoing share repurchases.

Given the combination of a CHMP-backed hemophilia asset, a sizable AI-enabled cardiometabolic partnership and the recent setback for ziltivekimab, the emphasis at that event will likely be on how Novo Nordisk plans to sustain double-digit earnings growth while managing clinical risk and competitive pressures in obesity and diabetes.

Stock price context for Novo Nordisk

In European trading referenced by Aktiencheck on September 18, 2026, Novo Nordisk shares climbed 3.6% intraday to 37.77 euros, representing a gain of about 25% compared with the cited 52-week low of 30.25 euros, as investors welcomed the CHMP recommendation for Frehemgo.

More news and analyses on Novo Nordisk stock